Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of KN057 in Hemophilia A or B
NCT05421429Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Armocibart in hemophilia A and hemophilia B (HB) (4 cohorts), sponsored by Alphamab Oncology. Primary endpoints: Treatment Emergent Adverse Events, Withdrawals due to Treatment Emergent Adverse Events and 5 more. Started Jul 2022; status: completed.
02
Drugs
Armocibart
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT05421429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421429.